Prothena's anti-amyloid therapy receives FDA fast track designation to treat Alzheimer’s
BioPharma-Reporter - 03-May-2022Guarantees higher efficacy, convenience and potential safety than other anti-Aβ therapies
Join the club for FREE to access the whole archive and other member benefits.
President and CEO of Prothena
Gene Kinney is the President and CEO of Prothena and had served as Chief Operating Officer and Chief Scientific Officer. Kinney is a member of Prothena’s founding leadership team, and held the position of Chief Scientific Officer and Head of Research and Development. Before joining Prothena, he was senior vice president at Elan Pharmaceuticals and held several senior positions at Merck Research Laboratories and Bristol Myers Squibb, and was an Assistant Professor at the Emory University School of Medicine.
Kinney earned his BA from Bloomsburg University and his MA and PhD from Florida Atlantic University.
Visit website: https://www.prothena.com/management/gene-g-kinney/
See also: Prothena - Clinical biotechnology company for neurodegenerative and rare peripheral amyloid diseases
Details last updated 03-Jul-2023
Guarantees higher efficacy, convenience and potential safety than other anti-Aβ therapies